A Phase I, Randomized, Double-blind, Placebo-controlled, Single and Multiple Doses Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PRT-064040 Nasal Spray in Healthy Adult Subjects
Latest Information Update: 09 Dec 2025
At a glance
- Drugs PRT 064040 (Primary)
- Indications Migraine
- Focus Adverse reactions
- Sponsors Sichuan Purity Pharmaceutical Technology
Most Recent Events
- 09 Dec 2025 New trial record